Abstract: Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
March 29, 2022
Assignee:
University of Kansas
Inventors:
Hiroshi Nishimune, Richard Barohn, Buddhadeb Dawn, Yomna Badawi, James W. Mitchell, Rupal Soder
Abstract: Provided herein are compositions and methods for degrading polymer systems. These compositions and methods can be used to effectively degrade a range of polymers commonly used in oil and gas operations, including polymers with carbon-carbon backbones such as polyacrylamides. Further, these compositions and methods can simultaneously degrade other organic molecules and pollutants associated with oil and gas operations. The compositions and methods described herein employ reactants that are more environmentally-friendly than conventional methods and components used in, for example, polymer breaking processes.
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
March 22, 2022
Assignee:
University of Kansas
Inventors:
Aaron M. Scurto, William Gilbert, Jenn-Tai Liang
Abstract: Examples of heat exchanger systems for active radiative cooling are described. In one example, the system includes a heat exchanger and a spectrally selective surface material on at least one surface of the heat exchanger. The spectrally selective surface material exhibits high reflectivity at shorter wavelengths and high emissivity at longer wavelengths. The system can also include an active cooling system in some cases to actively transfer heat to the heat exchanger. The use of spectrally selective surfaces that operate at temperatures exceeding that of the outdoor ambient for which convective losses augment radiation losses have advantages over passive cooling, such as but not limited to: providing a better match to cooling loads, reducing the heat rejection surface area required to achieve a desired cooling rate, and increasing the heat transferred to deep space through the atmospheric window so as to simultaneously cool infrastructure, devices, buildings, and Earth.
Abstract: A cannula device for draining sub-retinal fluid externally to the eye includes a shaft, an outer sleeve, and an inner sleeve. The outer sleeve and the inner sleeve have a curve therein to access the back of the eye externally. The outer sleeve is extendable relative to the inner sleeve and the shaft, and the outer sleeve includes a penetrative tip to penetrate the sclera and provide access to the sub-retinal fluid to the inner sleeve.
Abstract: A photocleavable heterobifunctional linker can include a structure of Formula (A) wherein coumarin is any coumarin or coumarin derivative; R, R9, and R10 are each independently a chemical moiety; R1 is a hydrogen, protecting group, leaving group, substrate, or capture entity; R2 is a hydrogen, hydroxyl, halide, alkoxy, anhydride, amino, protecting group, leaving group, substrate, or capture entity; L1 is a sub-linker; and L2 is a sub-linker. A capture device can include the photocleavable bifunctional linker having a structure of Formula (A) as provide herein, wherein R1 is a substrate. A method of capturing a target substance can include: providing the capture device having the photocleavable bifunctional linker with the structure of Formula (A) and contacting a target substance to the capture moiety such that the target substance is captured. Irradiating the linker with light can cleave the linker, thereby releasing the target substance from the substrate.
Type:
Application
Filed:
December 20, 2019
Publication date:
February 24, 2022
Applicant:
The University of Kansas
Inventors:
Steven Allan Soper, Blake R. Peterson, Richard S. Givens
Abstract: An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers.
Type:
Application
Filed:
November 2, 2021
Publication date:
February 24, 2022
Applicants:
The University of Kansas, The Children's Mercy Hospital
Inventors:
Michael Detamore, Lindsey Ott, Robert Weatherly
Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.
Type:
Grant
Filed:
January 25, 2018
Date of Patent:
February 8, 2022
Assignees:
Northwestern University, The United States of Americans represented by the Secretary, Department of Health and Human Services, University of Kansas
Inventors:
Congcong He, Sui Huang, Chen Wang, Altea Rocchi, Juan Jose Marugan, Marc Ferrer, Samarjit Patnaik, Yuchi Chen, Kevin Frankowski, Frank J. Schoenen
Abstract: The present invention relates to methods of using a therapeutic system. In particular, the present invention relates to procedures and methods of using a system having hardware, software, and appliance components for assessing and entraining a non-nutritive suck (NNS) pattern in a patient. The methods include configuring the hardware and software systems to receive data from an orofacial stimulation appliance and to generate a precise therapeutic pulse profile that is actuated as a tactile stimulus. The methods also include collecting data using the orofacial stimulation appliance and delivering the tactile stimulus via the orofacial stimulation appliance to entrain an organized NNS pattern.
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
February 1, 2022
Assignees:
Innara Health, Inc., University of Kansas
Inventors:
Steven M. Barlow, David L. Stalling, Kenneth Aron
Abstract: The present invention includes novel compounds and methods for preventing or treating diseases associated with N-linked glycosylation in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound of the invention.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
January 11, 2022
Assignees:
YALE UNIVERSITY, THE UNIVERSITY OF KANSAS
Inventors:
Joseph N. Contessa, Jennifer E. Golden, Daniel P. Flaherty
Abstract: The disclosure provides human toll-like receptor modulators of general Formula (II), wherein R1, R2, R3, R4, R5, R6, R7, R8 are defined herein.
Type:
Application
Filed:
September 10, 2021
Publication date:
January 6, 2022
Applicant:
University of Kansas
Inventors:
Sunil A. David, Mallesh Beesu, Giuseppe Caruso, Alex Salyer
Abstract: The disclosure is directed to polyelectrolyte complex nanoparticles that can be used to deliver agents deep into hydrocarbon reservoirs. Methods of making and using said polyelectrolyte complex nanoparticles are also provided.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
November 30, 2021
Assignees:
CONOCOPHILLIPS COMPANY, UNIVERSITY OF KANSAS
Inventors:
Ying-Ying Lin, Cory Berkland, Jenn-Tai Liang, Ahmad Moradi-Araghi, Terry M. Christian, Riley B. Needham, James H. Hedges, Min Cheng, Faye L. Scully, David R. Zornes
Abstract: The disclosure provides methods of treating cancer by selectively inhibiting p-S552-?-catenin, p-T217-?-catenin, p-T332-?-catenin, and/or p-S675-?-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.
Type:
Grant
Filed:
July 28, 2016
Date of Patent:
November 16, 2021
Assignees:
UNIVERSITY OF CONNECTICUT, UNIVERSITY OF KANSAS, STOWERS INSTITUTE FOR MEDICAL RESEARCH
Inventors:
Rajeswari Kasi, Linheng Li, Xiuling Lu, John M. Perry, Gurusingham Sitta Sittampalam, Anuradha Roy, Xi C. He
Abstract: Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.
Type:
Grant
Filed:
April 21, 2021
Date of Patent:
November 2, 2021
Assignees:
The University of Kansas, Kansas State University Research Foundation
Abstract: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
Type:
Grant
Filed:
July 9, 2020
Date of Patent:
November 2, 2021
Assignees:
The Children's Mercy Hospital, The University of Kansas
Inventors:
Amara Seng, Ryan Fischer, Thomas Yankee, Mary Markiewicz, John Szarejko
Abstract: Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complement of the nucleotide sequence, and methods of using the vectors, are provided.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
October 12, 2021
Assignees:
University of Iowa Research Foundation, University of Kansas
Inventors:
Ziying Yan, John F. Engelhardt, Jianming Qiu, Zekun Wang
Abstract: The invention is directed to polymers that self-crosslink at acidic pH or can be crosslinked by phenolic agents in brine. Such polymers have lower viscosity and can be pumped deep into reservoirs, where they will cross link in situ, thus increasing their viscosity and/or form a gel and blocking thief zones. Methods of making and using such polymers are also provided.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
October 5, 2021
Assignees:
University of Kansas, Conocophilllips Company
Inventors:
Huili Guan, Cory Berkland, Ahmad Moradi-Araghi, Jenn-Tai Liang, Terry M. Christian, Riley B. Needham, James H. Hedges, Min Cheng, Faye L. Scully
Abstract: Embodiments of the present invention relate to systems, methods, and apparatus for immobilizing and/or securing bone portions. Particularly, at least one embodiment involves a compact anti-rotation device that can secure adjacent bones and/or bone portions in a manner that prevents or limits relative rotational movement thereof.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
September 28, 2021
Assignee:
University of Kansas
Inventors:
Terence Edward McIff, Edward Bruce Toby
Abstract: The disclosure provides human toll-like receptor modulators of general Formula (II), wherein R1, R2, R3, R4, R5, R6, R7, R8 are defined herein.
Type:
Grant
Filed:
August 19, 2016
Date of Patent:
September 28, 2021
Assignee:
University of Kansas
Inventors:
Sunil A. David, Mallesh Beesu, Giuseppe Caruso, Alex Salyer
Abstract: The present disclosure is directed, among other things, to the surprising and unexpected efficacy provided by select V2R antagonists in significantly reducing the cell proliferation levels of clear cell renal cell carcinoma. Thus, the present disclosure provides methods, uses, and medicaments that include such select V2R antagonists for utility in treating clear cell renal cell carcinoma.
Abstract: Provided herein are compounds of the formulas: wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.
Type:
Grant
Filed:
January 29, 2020
Date of Patent:
August 24, 2021
Assignee:
UNIVERSITY OF KANSAS
Inventors:
Brian S. J. Blagg, Rick T. Dobrowsky, Mercy Anyika